After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Earlier, Yahoo Finance discussed this stock as it revealed Allogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Venture in Asia.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
Allogene Therapeutics Inc is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. At the end of the last regular session, the stock closed at $4.79 and fluctuated between $4.9550 as its day high and $4.7600 as its day low. The current market capitalization of Allogene Therapeutics Inc is $806.06M. A total of 1.31 million shares were traded on the day, compared to an average of 3.08M shares.
Additionally, investors take into account insider trades when predicting how a stock will perform. During the recent three months, ALLO has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 16 BUYs and 5 SELLs from insiders. Insiders purchased 6,234,994 shares during that period but sold 100,198.
In the most recent transaction, MESSEMER DEBORAH M. sold 18,640 shares of ALLO for 2.70 per share on Dec 18. After the transaction, the Director now owns 62,456 company shares. In a previous transaction on Aug 07, Mayo Stephen sold 10,000 shares at 4.29 per share. ALLO shares that Director owns now total 25,328.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. According to analysts who have offered 12-month price targets for ALLO in the last 3 months, the mean price target is $11.75 with high estimates of $35.00 and low estimates of $4.50. In terms of 52-week highs and lows, ALLO has a high of $7.30 and a low of $2.23.
As of this writing, ALLO has an earnings estimate of -$0.45 per share for the current quarter. EPS was calculated based on a consensus of 16 estimates, with a high estimate of -$0.34 per share and a lower estimate of -$0.62. The company reported an EPS of -$0.53 in the last quarter, which was 10.20% higher than expectations of -$0.59.
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. ALLO’s latest balance sheet shows that the firm has $457.30M in Cash & Short Term Investments as of fiscal 2021. There were $73.13M in debt and $48.17M in liabilities at the time. Its Book Value Per Share was $3.47, while its Total Shareholder’s Equity was $916.41M.
Analysts Opinion
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ALLO is Buy with a score of 4.39.
